Drug Trial Radar · NCT05464420
A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)
Last checked: Nov 19, 2026Latest source record: Sep 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,162
Actual
Start
Aug 12, 2022
Primary completion
May 25, 2023
Study completion May 25, 2023
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jul 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 49 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, and immunogenicity of a pneumococcal 21-valent conjugate vaccine (V116) in pneumococcal vaccine-naïve adults 18 to 49 years of age. The primary study hypothesis is that all 3 lots of V116 are equivalent as assessed by the serotype-specific opsonophagocytic activity (OPA) Geometric Mean Titers (GMTs) at 30 days postvaccination for all serotypes included in V116.
Conditions
- Pneumococcal Disease
Interventions
V116Biological
Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
PPSV23Biological
Pneumococcal 23-valent conjugate vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Solicited Injection-site Adverse Events (AEs) Following Vaccination With Separate V116 LotsTime frame: Up to 5 days
- Percentage of Participants With Solicited Injection-site AEs Following Vaccination: Combined Lots of V116 or PPSV23Time frame: Up to 5 days
- Percentage of Participants With Solicited Systemic AEs Following Vaccination With Separate V116 LotsTime frame: Up to 5 days
- Percentage of Participants With Solicited Systemic AEs Following Vaccination: Combined Lots of V116 or PPSV23Time frame: Up to 5 days
- Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs) Following Vaccination With Separate V116 LotsTime frame: Up to 194 days
- Percentage of Participants With Vaccine-related SAEs Following Vaccination: Combined Lots of V116 or PPSV23Time frame: Up to 194 days
- Geometric Mean Titers (GMTs) of Serotype-specific Opsonophagocytic Activity (OPA) for All Serotypes in V116 Following Vaccination With Separate V116 LotsTime frame: Day 30
Locations
72 sites in 8 countries. Site status is shown where the registry gives one.
Desert Clinical Research/ CCT Research ( Site 0019)
Mesa, Arizona
Fiel Family and Sports Medicine, PC/CCT Research ( Site 0008)
Tempe, Arizona
Baptist Health Center For Clinical Research ( Site 0015)
Little Rock, Arkansas
Valley Clinical Trials, Inc. ( Site 0023)
Northridge, California
Artemis Institute for Clinical Research ( Site 0027)
San Diego, California
Millennium Clinical Trials ( Site 0004)
Simi Valley, California
Diablo Clinical Research, Inc. ( Site 0022)
Walnut Creek, California
Lynn Institute of Denver ( Site 0003)
Aurora, Colorado
Indago Research & Health Center, Inc ( Site 0011)
Hialeah, Florida
L&C Professional Medical Research Institute ( Site 0012)
Miami, Florida
Headlands Research Orlando ( Site 0017)
Orlando, Florida
Clinical Research Trials of Florida ( Site 0001)
Tampa, Florida
Clinical Research Prime Rexburg ( Site 0040)
Rexburg, Idaho
Healthcare Research Network - Chicago ( Site 0006)
Flossmoor, Illinois
Kentucky Pediatric/ Adult Research ( Site 0036)
Bardstown, Kentucky
Alliance for Multispecialty Research, LLC ( Site 0031)
Kansas City, Missouri
Methodist Physicians Clinic/CCT Research ( Site 0029)
Fremont, Nebraska
Healor Primary Care / CCT Research ( Site 0028)
Las Vegas, Nevada
Axces Research ( Site 0034)
Santa Fe, New Mexico
Rochester Clinical Research, Inc. ( Site 0033)
Rochester, New York
M3 Wake Research Associates ( Site 0035)
Raleigh, North Carolina
Lynn Health Science Institute ( Site 0014)
Oklahoma City, Oklahoma
Velocity Clinical Research, Providence ( Site 0018)
East Greenwich, Rhode Island
Velocity Clinical Research, Greenville ( Site 0021)
Greenville, South Carolina
Clinical Research Associates Inc ( Site 0039)
Nashville, Tennessee
DCOL Center for Clinical Research ( Site 0025)
Longview, Texas
IMA Clinical Research San Antonio ( Site 0020)
San Antonio, Texas
Dynamed Clinical Research, LP d/b/a DM Clinical Research ( Site 0016)
Tomball, Texas
Charlottesville Medical Research ( Site 0013)
Charlottesville, Virginia
Health Research of Hampton Roads, Inc. ( Site 0002)
Newport News, Virginia
Medizinische Universität Wien ( Site 0302)
Vienna, Austria
Tropeninstitut Wien 1060 ( Site 0300)
Vienna, State of Vienna, Austria
Medizinische Universität Graz-Klinische Abteilung für Pulmonologie ( Site 0304)
Graz, Styria, Austria
Medizinische Universitaet Innsbruck ( Site 0301)
Innsbruck, Tyrol, Austria
Colchester Research Group ( Site 0202)
Truro, Nova Scotia, Canada
Hamilton Medical Research Group ( Site 0208)
Hamilton, Ontario, Canada
Milestone Research Inc. ( Site 0201)
London, Ontario, Canada
Manna Research Toronto ( Site 0209)
Toronto, Ontario, Canada
Manna Research Mirabel ( Site 0207)
Mirabel, Quebec, Canada
Manna Research Montreal ( Site 0203)
Pointe-Claire, Quebec, Canada
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.